Ovarian Cancer – Pipeline Review, H2 2015 – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/ddpcn7/ovarian_cancer)
has announced the addition of the “Ovarian
Cancer – Pipeline Review, H2 2015″ report to their offering.
This report provides comprehensive information on the therapeutic
development for Ovarian Cancer, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Ovarian
Cancer and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MoAs to produce
first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Ovarian Cancer Overview
- Therapeutics Development
- Pipeline Products for Ovarian Cancer – Overview
- Pipeline Products for Ovarian Cancer – Comparative Analysis
- Ovarian Cancer – Therapeutics under Development by Companies
-
Ovarian Cancer – Therapeutics under Investigation by
Universities/Institutes - Ovarian Cancer – Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Ovarian Cancer – Products under Development by Companies
-
Ovarian Cancer – Products under Investigation by
Universities/Institutes - Ovarian Cancer – Companies Involved in Therapeutics Development
Companies Mentioned:
- 3-V Biosciences, Inc.
- 4SC AG
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AB Science SA
- AbbVie Inc.
- Abeona Therapeutics, Inc.
- AbGenomics International, Inc.
- Acetylon Pharmaceuticals, Inc.
- Adaptimmune Limited
- Aduro BioTech, Inc.
- Advanced Accelerator Applications SA
- Advantagene, Inc.
- Advaxis, Inc.
- Advenchen Laboratories, LLC
- Aeterna Zentaris Inc.
- Agilvax, Inc.
- Alchemia Limited
- Alethia Biotherapeutics Inc.
- Almac Discovery Limited
- Ambrx, Inc.
- Amgen Inc.
- Anavex Life Sciences Corp.
- ANP Technologies, Inc.
- Antoxis Limited
- Aphios Corporation
- Aposense Ltd.
- Aprea AB
- arGEN-X BV
- Armour Therapeutics Inc.
- (200+ Others)
For more information visit http://www.researchandmarkets.com/research/ddpcn7/ovarian_cancer
Contacts
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology,
Women’s
Health, Ovarian
Cancer